(BIM) Biomerieux - Overview
Stock: Chromogenic Media, Blood Culture, PCR Systems, Mass Spectrometry, AST
Dividends
| Dividend Yield | 0.74% |
| Yield on Cost 5y | 0.75% |
| Yield CAGR 5y | 9.76% |
| Payout Consistency | 96.0% |
| Payout Ratio | 28.4% |
| Risk 5d forecast | |
|---|---|
| Volatility | 24.3% |
| Relative Tail Risk | -5.97% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.91 |
| Alpha | -20.77 |
| Character TTM | |
|---|---|
| Beta | 0.019 |
| Beta Downside | 0.142 |
| Drawdowns 3y | |
|---|---|
| Max DD | 26.11% |
| CAGR/Max DD | 0.09 |
Description: BIM Biomerieux January 03, 2026
bioMérieux S.A. (ticker BIM) designs, manufactures and sells in-vitro diagnostic (IVD) products for infectious disease detection across clinical and industrial markets worldwide. Its portfolio spans culture media (CHROMID), automated blood-culture systems (BACT/ALERT VIRTUO), multiplex PCR platforms (BIOFIRE, BIOFIRE SPOTFIRE), mass-spectrometry identification (VITEK MS), automated ID/AST solutions (VITEK 2, VITEK REVEAL, ETEST), whole-genome sequencing tools (EPISEQ CS), and a suite of software and consumables that support laboratory workflow and antimicrobial-resistance monitoring.
Key drivers for bioMérieux’s performance include: (1) Revenue growth of roughly 7 % YoY in 2023, propelled by rising demand for rapid-turnaround diagnostics and a 12 % increase in R&D spend to sustain pipeline innovation; (2) Operating margins expanding to ~18 % as the company leverages scale in its VITEK and BIOFIRE lines while maintaining a strong recurring-revenue stream from software and service contracts; (3) Sector-wide tailwinds such as the global IVD market’s projected CAGR of 5–6 % through 2030, driven by aging populations, heightened focus on antimicrobial-resistance surveillance, and the shift toward point-of-care testing in emerging regions (Africa, Middle East, APAC). These macro trends, combined with bioMérieux’s diversified geographic footprint, underpin its growth outlook.
If you want a data-rich, model-driven assessment of BIM’s valuation and risk profile, a quick look at ValueRay’s analyst toolkit can provide the quantitative depth you need.
Piotroski VR‑10 (Strict, 0-10) 9.5
| Net Income: 660.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 8.46 > 1.0 |
| NWC/Revenue: 18.68% < 20% (prev 19.94%; Δ -1.26% < -1%) |
| CFO/TA 0.24 > 3% & CFO 1.28b > Net Income 660.4m |
| Net Debt (125.9m) to EBITDA (1.53b): 0.08 < 3 |
| Current Ratio: 2.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (118.9m) vs 12m ago -0.04% < -2% |
| Gross Margin: 54.80% > 18% (prev 0.52%; Δ 5428 % > 0.5%) |
| Asset Turnover: 128.2% > 50% (prev 106.6%; Δ 21.57% > 0%) |
| Interest Coverage Ratio: 40.01 > 6 (EBITDA TTM 1.53b / Interest Expense TTM 25.9m) |
Altman Z'' 2.93
| A: 0.24 (Total Current Assets 2.28b - Total Current Liabilities 1.00b) / Total Assets 5.37b |
| B: 0.03 (Retained Earnings 161.0m / Total Assets 5.37b) |
| C: 0.19 (EBIT TTM 1.03b / Avg Total Assets 5.31b) |
| D: -0.03 (Book Value of Equity -48.6m / Total Liabilities 1.43b) |
| Altman-Z'' Score: 2.93 = A |
Beneish M -3.36
| DSRI: 0.65 (Receivables 688.4m/865.5m, Revenue 6.81b/5.61b) |
| GMI: 0.95 (GM 54.80% / 51.83%) |
| AQI: 0.95 (AQ_t 0.28 / AQ_t-1 0.29) |
| SGI: 1.21 (Revenue 6.81b / 5.61b) |
| TATA: -0.12 (NI 660.4m - CFO 1.28b) / TA 5.37b) |
| Beneish M-Score: -3.36 (Cap -4..+1) = AA |
What is the price of BIM shares?
Over the past week, the price has changed by -3.07%, over one month by -17.42%, over three months by -10.06% and over the past year by -16.37%.
Is BIM a buy, sell or hold?
What are the forecasts/targets for the BIM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 120.1 | 26.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 94.9 | 0.1% |
BIM Fundamental Data Overview February 03, 2026
P/E Trailing = 30.8517
P/E Forward = 24.3309
P/S = 2.8014
P/B = 2.9337
P/EG = 1.9454
Revenue TTM = 6.81b EUR
EBIT TTM = 1.03b EUR
EBITDA TTM = 1.53b EUR
Long Term Debt = 212.8m EUR (from longTermDebt, last quarter)
Short Term Debt = 172.1m EUR (from shortTermDebt, last quarter)
Debt = 506.4m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 125.9m EUR (from netDebt column, last quarter)
Enterprise Value = 11.67b EUR (11.55b + Debt 506.4m - CCE 380.5m)
Interest Coverage Ratio = 40.01 (Ebit TTM 1.03b / Interest Expense TTM 25.9m)
EV/FCF = 19.59x (Enterprise Value 11.67b / FCF TTM 595.8m)
FCF Yield = 5.10% (FCF TTM 595.8m / Enterprise Value 11.67b)
FCF Margin = 8.75% (FCF TTM 595.8m / Revenue TTM 6.81b)
Net Margin = 9.70% (Net Income TTM 660.4m / Revenue TTM 6.81b)
Gross Margin = 54.80% ((Revenue TTM 6.81b - Cost of Revenue TTM 3.08b) / Revenue TTM)
Gross Margin QoQ = 57.09% (prev 51.87%)
Tobins Q-Ratio = 2.18 (Enterprise Value 11.67b / Total Assets 5.37b)
Interest Expense / Debt = 1.48% (Interest Expense 7.50m / Debt 506.4m)
Taxrate = 24.67% (52.6m / 213.2m)
NOPAT = 779.2m (EBIT 1.03b * (1 - 24.67%))
Current Ratio = 2.27 (Total Current Assets 2.28b / Total Current Liabilities 1.00b)
Debt / Equity = 0.13 (Debt 506.4m / totalStockholderEquity, last quarter 3.93b)
Debt / EBITDA = 0.08 (Net Debt 125.9m / EBITDA 1.53b)
Debt / FCF = 0.21 (Net Debt 125.9m / FCF TTM 595.8m)
Total Stockholder Equity = 3.94b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.43% (Net Income 660.4m / Total Assets 5.37b)
RoE = 16.76% (Net Income TTM 660.4m / Total Stockholder Equity 3.94b)
RoCE = 24.91% (EBIT 1.03b / Capital Employed (Equity 3.94b + L.T.Debt 212.8m))
RoIC = 18.32% (NOPAT 779.2m / Invested Capital 4.25b)
WACC = 5.79% (E(11.55b)/V(12.05b) * Re(5.99%) + D(506.4m)/V(12.05b) * Rd(1.48%) * (1-Tc(0.25)))
Discount Rate = 5.99% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.02%
[DCF Debug] Terminal Value 88.43% ; FCFF base≈413.0m ; Y1≈509.5m ; Y5≈867.7m
Fair Price DCF = 213.0 (EV 25.27b - Net Debt 125.9m = Equity 25.14b / Shares 118.1m; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -9.53 | EPS CAGR: -47.24% | SUE: 0.0 | # QB: 0
Revenue Correlation: 9.02 | Revenue CAGR: 7.57% | SUE: 1.17 | # QB: 1
EPS next Year (2026-12-31): EPS=4.91 | Chg30d=-0.064 | Revisions Net=-3 | Growth EPS=+6.3% | Growth Revenue=+5.0%